PURE BIOSCIENCE, INC. Cash Flow Statement
PURE|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Operating Cash Flow
-$2M
FY2025
Free Cash Flow
N/A
FY2025
Capital Expenditures
N/A
Cash used for long-term assets
Dividends Paid
N/A
FY2025
PURE BIOSCIENCE, INC. used $2M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Negative shareholders equity: Liabilities exceed assets
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$2.4M | -$3.4M | -$4.0M | -$3.5M | -$2.3M | $4.0K | -$6.6M | -$7.4M | -$6.3M | -$14.4M | -$7.6M | -$11.1M | -$7.7M | -$8.9M | -$8.3M |
| Depreciation & Amortization | $2.0K | $148.0K | $117.0K | $213.0K | $172.0K | $192.0K | $241.0K | $285.0K | $276.0K | $219.0K | $206.0K | $248.0K | $311.0K | $385.0K | $471.0K |
| Operating Cash Flow | -$2.0M | -$2.5M | -$3.3M | -$2.4M | -$1.2M | $669.0K | -$3.0M | -$3.9M | -$4.6M | -$5.0M | -$6.1M | -$6.3M | -$3.9M | -$5.6M | -$6.1M |
| Capital Expenditures | - | - | $33.0K | $81.0K | $521.0K | $58.0K | $7.0K | $19.0K | $206.0K | $390.0K | $81.0K | $21.0K | $12.0K | $10.0K | $14.0K |
| Free Cash Flow | - | - | -$3.3M | -$2.5M | -$1.7M | $611.0K | -$3.0M | -$3.9M | -$4.8M | -$5.4M | -$6.1M | -$6.3M | -$3.9M | -$5.6M | -$6.1M |
| FCF Margin | - | - | -177.0% | -137.8% | -45.6% | 8.8% | -157.0% | -220.2% | -260.4% | -417.5% | -842.8% | -1154.0% | -477.6% | -689.4% | -1322.8% |